TREVI THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.81 USD | -3.77% |
|
-10.37% | +109.70% |
| Mar. 20 | Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024 | |
| Mar. 20 | Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 194M |
|---|---|---|---|---|---|
| Net income 2024 * | -41M | Net income 2025 * | -53M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 116M | Net cash position 2025 * | 199M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-7.16
x | P/E ratio 2025 * |
-6.35
x | Employees | 25 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on Trevi Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -3.77% | ||
| 1 week | -10.37% | ||
| Current month | -18.55% | ||
| 1 month | -16.12% | ||
| 3 months | +97.89% | ||
| 6 months | +38.42% | ||
| Current year | +109.70% |
1 week
2.60
3.11
1 month
2.604.00
Current year
1.274.00
1 year
0.974.00
3 years
0.464.68
5 years
0.0010.62
10 years
0.0010.62
| Managers | Title | Age | Since |
|---|---|---|---|
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
Thomas Sciascia
FOU | Founder | 70 | 10-12-31 |
Lisa Delfini
DFI | Director of Finance/CFO | 54 | 21-08-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anne VanLent
BRD | Director/Board Member | 76 | 18-10-09 |
James Cassella
BRD | Director/Board Member | 69 | 20-02-12 |
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 2.81 | -3.77% | 56,947 |
| 24-04-12 | 2.92 | -2.01% | 93,540 |
| 24-04-11 | 2.98 | +9.16% | 160,686 |
| 24-04-10 | 2.73 | -5.21% | 242,358 |
| 24-04-09 | 2.88 | -8.13% | 557,946 |
Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT
More quotes
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.
Calendar
2024-04-25
- European Pulmonary Fibrosis Patient Summit
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.81
USD
Average target price
7.4
USD
Spread / Average Target
+163.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +109.70% | 201M | |
| -2.34% | 102B | |
| +2.31% | 97.22B | |
| +4.22% | 22.27B | |
| -16.72% | 20.84B | |
| -4.50% | 19.19B | |
| -41.75% | 16.76B | |
| -23.26% | 14.76B | |
| -0.02% | 13.54B | |
| +22.69% | 11.53B |
- Stock Market
- Equities
- TRVI Stock
